# An Electrochemical Hypothesis for Cancer

An Electrochemical Hypothesis for Cancer: GABAergic Dysregulation, Alpha-Ketoglutarate Accumulation, and Circadian Vulnerability in Oncogenic Transformation

Abstract

Cancer arises through progressive genetic and epigenetic alterations, yet fundamental questions remain regarding what creates permissive conditions for oncogenesis. This paper proposes an electrochemical framework linking cancer to disrupted GABAergic metabolic regulation systems via a novel thermodynamic mechanism. I hypothesize that metabolic phenotypes with deficient GABA pathway function experience simultaneous metabolic stagnation (thermodynamic inhibition via accumulated alpha-ketoglutarate) and " bio-electric instability " (circadian-dependent charge dysregulation), creating conditions favoring genomic instability and dysregulated proliferation. Central to this hypothesis is alpha-ketoglutarate's role as an oscillating charge intermediate between GABA metabolic pathways. Cancer emerges when these regulatory failures allow continuous adrenergic proliferative signaling without proper inhibitory control. This framework integrates established cancer hallmarks—metabolic reprogramming, circadian disruption, genomic instability, and aberrant growth signaling—into a unified mechanistic model with testable predictions regarding biomarker patterns, genetic associations, and therapeutic interventions targeting GABAergic restoration and chronotherapeutic optimization. This electrochemical framework should be understood as a conceptual systems-level hypothesis that integrates existing metabolic, circadian, and stress-biology data into a unified mechanistic model.

Keywords: cancer, GABA metabolism, circadian rhythm, alpha-ketoglutarate, adrenergic signaling, electrochemical regulation

Introduction

Cancer develops through accumulation of genetic alterations enabling sustained proliferative signaling, growth suppressor evasion, cell death resistance, and metastatic potential (1). While specific oncogenes and tumor suppressors have been identified, fundamental questions persist: Why do mutations accumulate non-randomly? What creates permissive cellular environments for transformation? Why do circadian disruption and chronic stress consistently elevate cancer risk (2,3)?

Gamma-aminobutyric acid (GABA) functions beyond its canonical neurotransmitter role. GABA metabolism intersects central carbon metabolism through the GABA shunt, bypassing two tricarboxylic acid (TCA) cycle steps while generating succinate and consuming alpha-ketoglutarate (4). This pathway appears throughout biology, suggesting fundamental bioenergetic rather than solely neuromodulatory functions (5). Emerging evidence reveals functional GABA signaling in cancer cells themselves, modulating proliferation, migration, and therapeutic resistance (6,7).

I propose that cancer susceptibility reflects failure of GABAergic charge regulation systems, specifically a collapse of cellular electrochemical potential. Deficient GABA pathway function creates two convergent metabolic stresses: accumulated alpha-ketoglutarate ("metabolic stagnation") and circadian-dependent charge dysregulation ("bio-electric instability"). Together, these produce genomic instability and remove inhibitory control over adrenergic proliferative signaling. I define “Bio-electric Instability” as the loss of the circadian-regulated electrochemical membrane potential that normally suppresses depolarization-induced proliferation.

The Hypothesis

Core Propositions

1. Cancer arises from dual GABAergic metabolic failures creating " metabolic stagnation " (alpha-ketoglutarate accumulation from deficient GABA shunt activity) and "bio-electric instability" (circadian charge dysregulation). Combined stresses create permissive conditions for oncogenesis.

2. Alpha-ketoglutarate accumulation represents the critical "in-between" metabolic state, oscillating between GABA metabolic pathways and disrupting epigenetic regulation through effects on alpha-ketoglutarate-dependent dioxygenases (8).

3. Circadian disruption creates vulnerability windows. Nighttime represents maximum oncogenic vulnerability when both stresses converge. DNA repair mechanisms show circadian oscillation with nighttime nadir (9,10).

4. Adrenergic signaling dysregulation drives proliferation. Loss of GABAergic inhibition allows sustained β-adrenergic receptor activation and continuous cAMP-PKA-CREB pathway stimulation (11,12).

The Alpha-Ketoglutarate 

Alpha-ketoglutarate occupies a critical metabolic position as TCA cycle intermediate, cofactor for dioxygenases regulating DNA/histone methylation, and substrate for biosynthetic pathways (8). Its homeostasis profoundly affects cellular function.

Normal regulation:

GABA shunt consumes alpha-ketoglutarate producing succinate

Glutamate dehydrogenase interconverts glutamate ↔ alpha-ketoglutarate

Tight homeostatic control maintained

Dysregulated state (deficient GABA pathway):

Reduced alpha-ketoglutarate consumption

Accumulation beyond homeostatic range

Dysregulated dioxygenase activity affecting:

TET enzymes (DNA demethylation) (13)

JmjC-domain histone demethylases (14)

Prolyl hydroxylases (HIF-1α regulation) (15)  altering the redox potential of the nuclear environment

This creates epigenetic instability—a hallmark cancer feature. Isocitrate dehydrogenase (IDH) mutations producing 2-hydroxyglutarate (competitive alpha-ketoglutarate inhibitor) drive oncogenesis precisely through dioxygenase dysregulation (16,17).

The " metabolic stagnation " mechanism: Accumulated alpha-ketoglutarate represents unresolved metabolic charge—an oscillating intermediate carrying reducing equivalents without appropriate discharge pathways. This charge imbalance disrupts:

Epigenetic homeostasis (altered dioxygenase activity)

Redox balance (perturbed NADH/NAD+ ratios)

Biosynthetic flux (dysregulated amino acid and collagen synthesis)

Oxygen sensing (aberrant HIF-1α stabilization)

Circadian Integration

GABA pathway function shows profound circadian dependence. Left GABA pathway deficiency manifests as "bio-electric instability"—charge dysregulation occurring specifically during nighttime when protective regulatory systems should activate.

Evidence supporting nighttime vulnerability:

1. Shift work carcinogenicity: The International Agency for Research on Cancer classifies shift work as "probably carcinogenic" based on substantial epidemiological evidence (18). Night shift workers show 40-80% elevated breast cancer risk (19,20).

2. Circadian clock genes as tumor suppressors: PER1, PER2, CRY2 mutations increase cancer susceptibility (21,22). These genes regulate cell cycle checkpoints, DNA damage responses, and apoptotic pathways (23).

3. DNA repair circadian oscillation: Nucleotide excision repair, base excision repair, and mismatch repair show circadian rhythmicity, with efficiency peaking mid-day and nadir at night (9,10,24).

4. Oxidative stress timing: Reactive oxygen species generation and antioxidant defense mechanisms oscillate circadianly, creating windows of vulnerability (25).

Mechanistic integration: During nighttime hours, when left GABA pathway should provide electrochemical charge regulation, deficiency creates "bio-electric instability." This converges with " metabolic stagnation " (accumulated alpha-ketoglutarate from right GABA pathway deficiency), creating maximum oncogenic vulnerability. DNA repair nadir coincides with peak metabolic stress, multiplicatively increasing mutation accumulation probability.

Adrenergic Signaling Dysregulation

Chronic stress substantially elevates cancer risk and worsens outcomes, mediated largely through sustained catecholamine release (26). β-adrenergic signaling promotes tumor growth, metastasis, angiogenesis, and therapeutic resistance (11,27).

Molecular mechanisms:

β-adrenergic receptors activate cAMP-PKA-CREB pathways

Sustained activation drives continuous proliferative gene expression

Promotes VEGF secretion enabling angiogenesis (28)

Inhibits anoikis facilitating metastasis (29)

Activates pro-survival signaling (Akt, ERK pathways) (30)

Hypothesis contribution: Normal GABAergic regulation maintains pulsatile rather than sustained adrenergic signaling through inhibitory control mechanisms. When GABA pathways fail, this inhibitory control disappears, allowing continuous β-adrenergic receptor activation. Physiological stress responses transform into oncogenic drivers.

Clinical support: β-blocker use associates with improved cancer outcomes in multiple studies. Breast cancer patients taking propranolol show reduced recurrence and improved survival (31,32). Retrospective analyses across cancer types suggest reduced cancer-specific mortality (33).

Alignment with Established Cancer Biology

Genomic Instability

Mechanism 1: Alpha-ketoglutarate disrupts epigenetic regulation

Accumulated alpha-ketoglutarate dysregulates TET enzymes controlling DNA methylation (13). Altered 5-methylcytosine and 5-hydroxymethylcytosine patterns can silence tumor suppressors or activate oncogenes. IDH mutations demonstrate this principle: 2-hydroxyglutarate competitively inhibits alpha-ketoglutarate-dependent dioxygenases, causing CpG island hypermethylation and histone methylation changes driving gliomagenesis and leukemogenesis (16,17,34).

Similarly, JmjC-domain histone demethylases require alpha-ketoglutarate as cofactor (14). Dysregulated levels alter histone methylation patterns, affecting chromatin accessibility and gene expression programs. This creates permissive epigenetic environments for oncogenic transformation.

Mechanism 2: Circadian DNA repair vulnerability

During nighttime (bio-electric instability peak), DNA repair efficiency drops substantially (9,10). Multiple repair pathways—nucleotide excision repair, base excision repair, mismatch repair—show circadian gating with nadir during subjective night. Mutations arising during this window persist, accumulating over time. Chronic circadian disruption (shift work, chronic jet lag) repeatedly exposes cells to high-vulnerability periods, multiplicatively increasing transformation probability.

Mechanism 3: Oxidative damage during vulnerability windows

Convergence of metabolic stagnation(alpha-ketoglutarate accumulation with perturbed redox balance) and bio-electric instability (reduced antioxidant defenses during nighttime) creates windows of maximal oxidative DNA damage (25). Reactive oxygen species directly modify DNA bases, creating mutagenic lesions. When DNA repair mechanisms simultaneously show reduced activity, these lesions fix as permanent mutations.

Metabolic Reprogramming

Cancer metabolism exhibits characteristic alterations aligning with hypothesis predictions:

1. Altered glutamate/alpha-ketoglutarate metabolism: Many cancers upregulate glutaminase (glutamine → glutamate) while showing variable glutamate dehydrogenase expression (35,36). This creates glutamate accumulation with impaired alpha-ketoglutarate interconversion, recapitulating predicted GABA shunt dysfunction. Some cancers show reduced GABA shunt enzyme expression, directly supporting the hypothesis. While the GABA shunt is traditionally viewed as a bypass, we propose that in cancer, it becomes a critical 'pressure release valve' for α-KG. When this valve fails (GABA deficiency), α-KG backlogs, forcing oncogenic epigenetic shifts.

2. Warburg effect connection: Aerobic glycolysis diverts carbon from TCA cycle oxidation (37). This affects alpha-ketoglutarate homeostasis by reducing isocitrate dehydrogenase flux while potentially increasing reductive carboxylation pathways. This may represent a compensatory response to fundamental GABA shunt dysfunction—an alternative strategy for managing alpha-ketoglutarate levels when normal GABA-mediated consumption fails.

3. Oncometabolite production: Beyond IDH mutations, various cancers show elevated metabolites interfering with alpha-ketoglutarate-dependent enzymes. This supports the central role of alpha-ketoglutarate homeostasis dysregulation in oncogenesis.

GABAergic Signaling in Tumors

Multiple cancer types express functional GABA receptors with proliferation-modulating effects:

Expression patterns:

GABA-A receptors: breast (40), colon (41), lung, prostate, glioblastoma (42), hepatocellular carcinoma (43)

GABA-B receptors: various cancers with context-dependent effects (44)

Functional consequences: GABA signaling can inhibit or promote proliferation depending on cancer type and receptor subunit composition (6,7). GABA influences invasion, migration, and cancer stem cell properties (43). Notably, cancer stem cells—the subpopulation driving tumor initiation and recurrence—show particular GABA sensitivity, with GABA-A activation affecting stem cell proliferation rates (43).

Metabolic enzyme alterations: Glutamate decarboxylase (GAD, synthesizing GABA from glutamate) and GABA transaminase (ABAT, degrading GABA) show altered expression in various cancers, creating disrupted GABA homeostasis supporting the hypothesis of fundamental GABAergic dysregulation.

Clinical correlations: GABA receptor expression correlates with prognosis in glioma, with specific subunit patterns associating with patient survival (44). This suggests GABAergic signaling actively influences tumor biology rather than representing epiphenomenon.

Testable Predictions

Biomarker Patterns

Prediction 1: Individuals at high cancer risk should exhibit:

Elevated plasma alpha-ketoglutarate, particularly during evening/nighttime hours

Reduced GABA/glutamate ratios showing circadian phase dependence

Disrupted circadian profiles of GABA metabolites

Elevated nighttime catecholamine excretion with sustained rather than pulsatile patterns

Prediction 2: Early-stage cancers should show:

Specific DNA and histone methylation signatures reflecting alpha-ketoglutarate dysregulation

Elevated 2-hydroxyglutarate even in IDH wild-type tumors

Disrupted circadian gene expression (PER, CRY, CLOCK, BMAL1)

Reduced GABA shunt enzyme expression

Prediction 3: Circadian biomarkers should predict risk:

Flattened circadian rhythms in metabolic markers

Phase-shifted or reduced amplitude melatonin profiles

Disrupted cortisol awakening response

Abnormal core body temperature rhythms

Genetic Associations

Prediction 4: Polymorphisms should modify cancer risk:

GABA metabolic enzymes (GAD1, GAD2, ABAT encoding GABA transaminase)

GABA receptors (GABRA/B/G gene families)

Glutamate dehydrogenase genes (GLUD1, GLUD2)

Circadian clock genes (PER1-3, CRY1-2, CLOCK, BMAL1, NPAS2)

Adrenergic receptor genes (ADRB1, ADRB2, ADRB3)

Prediction 5: Gene-gene and gene-environment interactions:

GABA pathway × circadian gene interactions predict cancer risk beyond additive effects

Circadian gene polymorphisms × shift work exposure show multiplicative risk increases

Adrenergic receptor variants × chronic stress exposure interact

Multi-gene risk scores incorporating GABA, circadian, and adrenergic pathways outperform single-pathway scores

Intervention Studies

Prediction 6: GABAergic modulation affects cancer outcomes:

GABA-A positive allosteric modulators (benzodiazepines, newer agents) administered during evening/nighttime reduce cancer incidence in high-risk populations

GABA transaminase inhibitors elevate endogenous GABA and show preventive effects

Interventions show circadian timing dependence, with evening administration more effective than morning

Prediction 7: Circadian optimization reduces risk:

Strict sleep-wake schedules with adequate sleep duration

Timed light exposure (bright light morning, dim light evening)

Avoidance or mitigation of shift work in genetically vulnerable individuals

Circadian-based lifestyle interventions reduce biomarker abnormalities

Prediction 8: Beta-blockade improves outcomes:

Propranolol or other β-blockers reduce cancer incidence in high-risk populations

β-blockers improve outcomes in established cancer, particularly when administered during vulnerability windows

Effects show dose and timing dependence

Prediction 9: Chronotherapy enhances treatment efficacy:

Chemotherapy administration timing substantially affects efficacy and toxicity

Optimal timing depends on individual chronotype and tumor circadian characteristics

Combined chronotherapy + GABAergic modulation + circadian optimization shows synergistic effects

Animal Model Predictions

Prediction 10: Combined genetic/environmental manipulations increase cancer susceptibility:

GABA-A receptor knockdown (tissue-specific, inducible) + chronic circadian disruption (jet lag protocol) shows dramatically elevated spontaneous tumor formation

GABA transaminase knockout + carcinogen exposure shows increased tumor incidence and accelerated progression

Effects show circadian timing dependence

Prediction 11: Carcinogen sensitivity depends on circadian phase:

Chemical or radiation carcinogen administration during subjective night (bio-electric instability peak) produces higher tumor incidence than daytime administration

Effect magnitude depends on GABA pathway genotype

Demonstrates mechanistic link between circadian timing and genomic instability

Therapeutic Implications

The therapeutic strategies outlined below translate the electrochemical hypothesis into testable intervention concepts. These are proposed as mechanism-based approaches requiring rigorous preclinical and clinical validation rather than established standards of care.

Prevention Strategies

1. GABAergic restoration during vulnerability windows (hypothesized): Low-dose GABA-A positive allosteric modulators administered evening/nighttime in high-risk individuals, pending future validation in biomarker-guided trials.

2. Metabolic interventions: Nutritional or pharmacological approaches targeting alpha-ketoglutarate homeostasis. Potential strategies include glutaminase inhibition in specific contexts, promotion of GABA shunt activity, or alpha-ketoglutarate supplementation (paradoxically, in some contexts exogenous alpha-ketoglutarate might normalize homeostasis by feedback regulation).

3. Circadian optimization: Evidence-based circadian hygiene protocols including strict sleep-wake schedules, timed light exposure, meal timing, exercise timing, and avoidance of circadian disruptors. Particularly critical for individuals with circadian gene polymorphisms or occupational circadian disruption.

4. Beta-blockade in high-risk populations (proposed): Propranolol or other β-blockers in individuals showing elevated catecholamine biomarkers, chronic stress exposure, or genetic vulnerability, requiring prospective clinical validation.

Treatment Enhancement

1. Chronotherapeutic optimization (requires clinical refinement): Timing chemotherapy and radiation to circadian phases maximizing efficacy while minimizing toxicity, with the hypothesis that adjunct GABA-based interventions could enable phase optimization; these combined strategies remain to be systematically tested (46,47).

2. Metabolic targeting: Therapeutic strategies addressing dysregulated glutamine/glutamate/alpha-ketoglutarate metabolism. Combined targeting of glutamine metabolism through glutaminase inhibition has emerged as a promising strategy in multiple cancer types, and in this framework, co-modulation of GABA pathways is hypothesized to produce additional, mechanism-based synergy that remains to be experimentally tested (48).

3. GABAergic adjuncts: GABA-A modulation as adjunct therapy to restore inhibitory control over proliferative signaling, enhance circadian rhythm robustness, reduce treatment-related stress responses, and potentially exert direct anti-tumor effects via cancer cell GABA receptors.

4. Integrated approaches: Combining chronotherapy + metabolic targeting + GABAergic modulation + beta-blockade based on individual tumor and host characteristics. Precision oncology incorporating circadian and metabolic phenotyping alongside genomic profiling.

Limitations

1. Phenotype definition: The hypothesis requires precise operational criteria for identifying vulnerable metabolic phenotypes. Validated biomarker panels measuring GABA pathway function, alpha-ketoglutarate homeostasis, circadian robustness, and adrenergic tone need development.

2. Mechanism specificity: While the systems-level framework integrates diverse observations, precise molecular mechanisms linking GABAergic charge regulation to specific oncogenic pathways require elucidation. Reduction from systems hypothesis to testable molecular mechanisms remains ongoing.

3. Individual variability: Not all individuals with proposed vulnerabilities develop cancer. Additional genetic, environmental, and stochastic factors clearly contribute. The hypothesis provides necessary but not sufficient conditions for oncogenesis.

4. Cancer type specificity: Different cancer types may show varying dependence on these mechanisms. Some cancers might arise primarily through GABAergic dysregulation, while others involve multiple independent pathways. Identifying which cancers show strongest mechanistic links remains crucial.

Conclusions

I propose that cancer susceptibility reflects failure of ancient GABAergic charge regulation systems managing alpha-ketoglutarate homeostasis and circadian charge balance. Vulnerable phenotypes experience simultaneous metabolic stagnation (accumulated alpha-ketoglutarate from deficient GABA shunt activity) and bio-electric instability (circadian charge dysregulation), creating genomic instability through charge-induced DNA damage, epigenetic dysregulation, and convergence with DNA repair vulnerability windows.

Central to this framework is alpha-ketoglutarate's role as an oscillating charge intermediate—the "in-between" state linking GABA metabolism to epigenetic regulation via alpha-ketoglutarate-dependent dioxygenases. Cancer emerges when adrenergic proliferative signaling loses GABAergic inhibitory control, transforming physiological stress responses into oncogenic drivers.

This hypothesis aligns with established cancer biology: genomic instability through multiple convergent mechanisms; metabolic reprogramming affecting glutamine, glutamate, and alpha-ketoglutarate pathways; circadian disruption creating vulnerability windows; aberrant adrenergic signaling driving proliferation and metastasis; and GABAergic dysregulation in tumors themselves.

The framework generates specific testable predictions regarding circadian-dependent biomarker patterns, genetic associations with gene-environment interactions, animal models requiring combined manipulations, and therapeutic interventions targeting GABAergic restoration, chronotherapeutic optimization, metabolic normalization, and adrenergic blockade.

If validated, this approach enables phenotype-based risk stratification, preventive strategies for high-risk individuals, chronotherapeutic interventions matching vulnerability windows, and integrated treatment approaches addressing fundamental electrochemical dysregulation rather than downstream consequences alone.



Author Information

Name: IL WOONG CHOI

Affiliation: Independent Researcher

Location: Oxford, United Kingdom

Email: iwchoikr@gmail.com

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The author declares no competing interests.

Ethics Approval

Not applicable.

Data Availability

Not applicable - no datasets were generated or analyzed during this study.

Declaration of Generative AI and AI-Assisted Technologies

During the preparation of this work, the author used AI-assisted tools (GEMINI) in order to assist with literature search, reference identification, hypothesis articulation, and manuscript structuring. After using these tools, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.



References

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

Touitou Y, Reinberg A, Touitou D. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock. J Pineal Res. 2017;63(4):e12371.

Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5(10):617-625.

Shelp BJ, Bown AW, McLean MD. Metabolism and functions of gamma-aminobutyric acid. Trends Plant Sci. 1999;4(11):446-452.

Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol. 2002;213:1-47.

Young SZ, Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology. 2009;24:171-185.

Andäng M, Hjerling-Leffler J, Moliner A, et al. Histone H2AX-dependent GABA(A) receptor regulation of stem cell proliferation. Nature. 2008;451(7177):460-464.

Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518(7539):413-416.

Sancar A, Lindsey-Boltz LA, Kang TH, Reardon JT, Lee JH, Ozturk N. Circadian clock control of the cellular response to DNA damage. FEBS Lett. 2010;584(12):2618-2625.

Gaddameedhi S, Selby CP, Kaufmann WK, Sancar A. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci USA. 2011;108(46):18790-18795.

Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201-1206.

Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939-944.

Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.

Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7(9):715-727.

Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402.

Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.

Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.

Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8(12):1065-1066.

Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 2001;93(20):1563-1568.

Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol. 2009;38(4):963-970.

Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111(1):41-50.

Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375-382.

Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9(12):886-896.

Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci USA. 2009;106(8):2864-2869.

Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1. Genes Dev. 2006;20(14):1868-1873.

Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology. Nat Rev Cancer. 2006;6(3):240-248.

Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042-7052.

Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514-4521.

Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12(2):369-375.

Kim-Fuchs C, Le CP, Pimentel MA, et al. Chronic stress accelerates pancreatic cancer growth and invasion. J Clin Invest. 2014;124(5):2059-2072.

Powe DG, Voss MJ, Zänker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-638.

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29(19):2635-2644.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73(3):250-260.

Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.

DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350.

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427-433.

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.

Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 2007;67(20):9704-9712.

Maemura K, Shiraishi N, Sakagami K, et al. Proliferative effects of gamma-aminobutyric acid on the gastric cancer cell line are associated with extracellular signal-regulated kinase 1/2 activation. J Gastroenterol Hepatol. 2009;24(4):688-696.

Blanchart A, Fernando R, Häring M, et al. Endogenous GABA controls migration and differentiation of adult-born neurons in the developing mouse olfactory bulb. J Neurosci. 2006;26(45):11729-11741.

Minuk GY, Gauthier T. The effect of gamma-aminobutyric acid on hepatic regenerative activity following partial hepatectomy in rats. Gastroenterology. 1993;104(1):217-221.

Schuller HM, Al-Wadei HA, Majidi M. Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis. 2008;29(10):1979-1985.

Young SZ, Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda). 2009;24:171-185.

Badalotti R, Dalmolin M, Malafaia O, Ribas Filho JM, Roesler R, Fernandes MAC, Isolan GR. Gene Expression of GABAA Receptor Subunits and Association with Patient Survival in Glioma. Brain Sci. 2024;14(3):275.

Schrader LA, Ronnekleiv-Kelly SM, Hogenesch JB, Bradfield CA, Malecki KM. Circadian disruption, clock genes, and metabolic health. J Clin Invest. 2024;134(13):e170998.

Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377-421.

Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Lévi FA. The circadian timing system in clinical oncology. Ann Med. 2014;46(4):191-207.

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–433.

